for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AB Science SA

ABS.PA

Latest Trade

3.90EUR

Change

-0.05(-1.27%)

Volume

31,900

Today's Range

3.85

 - 

3.95

52 Week Range

3.10

 - 

5.38

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
3.95
Open
3.88
Volume
31,900
3M AVG Volume
0.74
Today's High
3.95
Today's Low
3.85
52 Week High
5.38
52 Week Low
3.10
Shares Out (MIL)
41.60
Market Cap (MIL)
171.80
Forward P/E
4.67
Dividend (Yield %)
--

Next Event

Ab Science SA Annual Shareholders Meeting

Latest Developments

More

AB Science Provides Update On Masitinib Programs Timelines

AB Science H1 Operating Loss Narrows To 10.6‍​ Million Euros

AB Science Raises EUR 10 Mln In Private Placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AB Science SA

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The Company is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.

Industry

Biotechnology & Drugs

Contact Info

3 avenue George V

+33.1.47200014

http://www.ab-science.com/

Executive Leadership

Alain Moussy

Chairman of the Board, Chief Executive Officer

Denis Gicquel

Deputy Chief Executive Officer

Laurent Guy

Chief Financial Officer

Jean-Pierre Kinet

Director

Patrick Moussy

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (EUR)

2016

-0.780

2017

-0.750

2018

-0.690

2019(E)

0.845
Price To Earnings (TTM)
--
Price To Sales (TTM)
106.05
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-438.51
Return on Equity (TTM)
-103.79

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up